Quince Therapeutics files for $200M mixed securities shelf [Seeking Alpha]
Quince Therapeutics, Inc. (NASDAQ: QNCX) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $9.00 price target on the stock.
Quince Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Quince Therapeutics Presents Data from Prior Phase 3 ATTeST Clinical Trial at 2024 International Congress for Ataxia Research
Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting